申请人:Cortex Pharmaceuticals, Inc.
公开号:US20020055508A1
公开(公告)日:2002-05-09
Compounds of general structural formula (1) are shown to have AMPA receptor enhancing properties. The compounds are useful for such therapeutic purposes as facilitating the learning of behaviors dependent upon AMPA receptors, and in treating conditions, such as memory impairment, in which AMPA receptors, or synapses utilizing these receptors, are reduced in numbers or efficiency. They may also be used to enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior.
1
通用结构式(1)的化合物被证明具有增强AMPA受体的性质。这些化合物可用于促进依赖于AMPA受体的行为的学习,并用于治疗存在AMPA受体或利用这些受体的突触数量或效率减少的情况,例如记忆障碍。它们也可以用于增强兴奋性突触活动,以恢复大脑亚区之间的不平衡,如治疗精神分裂症或类精神分裂行为。1